Article Information
- Received October 23, 1998
- Revision received December 22, 1998
- Accepted December 28, 1998
- First published March 15, 1999.
- Version of record published March 15, 1999.
Author Information
Author contributions
Disclosures
- Received October 23, 1998.
- Revision received December 22, 1998.
- Accepted December 28, 1998.
This work was supported by postdoctoral fellowships from the National Multiple Sclerosis Society to D.E.S. and from the Howard Hughes Medical Institute and the Bushell Fellowship of the Royal Australasian College of Physicians to T.J.K., by predoctoral fellowships from the Department of Defense and the National Institutes of Health to T.S.Z., and by grants from the National Institutes of Health to W.E. and G.L. We thank Danny Ortuño, Patrick Burrola, and Darcie Baynes for excellent technical assistance, Stefano Bertuzzi for help with RNase protection assays, Dan Peterson of the Gage laboratory for use of their confocal microscope, Jill Meisenhelder for peptide synthesis, and Bob Hyman for kindly providing anti-Thy-1 antibodies.
Correspondence should be addressed to Dr. Greg Lemke, Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037.
Dr. Kilpatrick’s present address: Neuroimmunology Laboratory, Walter and Eliza Hall Institute of Medical Research, Royal Parade, Parkville 3052, Melbourne, Australia.
Online Impact